Form 8-K - Current report:
SEC Accession No. 0001104659-21-043948
Filing Date
2021-03-30
Accepted
2021-03-30 16:50:35
Documents
14
Period of Report
2021-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2110788d2_8k.htm   iXBRL 8-K 26571
2 EXHIBIT 99.1 tm2110788d2_ex99-1.htm EX-99.1 82937
6 GRAPHIC image_001.jpg GRAPHIC 141256
  Complete submission text file 0001104659-21-043948.txt   490912

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA casi-20210330.xsd EX-101.SCH 3187
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20210330_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20210330_pre.xml EX-101.PRE 22711
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2110788d2_8k_htm.xml XML 3590
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 21786816
SIC: 2836 Biological Products, (No Diagnostic Substances)